Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations
Highlights of the Trial
The study provides critical evidence regarding the minimum effective dose of the yellow fever vaccine in pediatric populations. Key highlights include:
- A low-dose (500 IU) regimen of the 17D-204 yellow fever vaccine failed to meet the -10% non-inferiority margin for seroconversion compared to the standard dose in infants aged 9–12 months.
- The seroconversion rate was 93% for the 500 IU dose versus 99% for the standard dose, representing a significant clinical gap in immunogenicity.
- Safety outcomes were comparable between the groups, with no serious adverse events attributed to the vaccination.
- Current WHO recommendations for fractional dosing in outbreak settings should not be extended to routine infant immunization programs.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.